Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

sed by sanofi-aventis.

Research and development expenses were $6.4 million and $5.3 million for the three months ended September 30, 2007 and September 30, 2006, respectively. The increase during the 2007 period was primarily due to an increase in spending of $2.1 million related to clinical development, regulatory filings and manufacturing of L-MTP-PE, and clinical development of UVIDEM. The increase was partially offset by a $0.4 million reduction in spending associated with development activities related to products currently on hold, as well as a $0.8 million reduction associated with lower headcount and termination of a lease agreement for certain of the Company's Paris facilities.

Selling, general and administrative expenses were $2.7 million and $1.8 million for the three months ended September 30, 2007 and 2006, respectively. The increase of $0.9 million in 2007 included $0.3 million of bonus accruals, $0.2 million of stock compensation expense and $0.2 million of consulting and salary expense.

Net interest income was $3.1 million for the three months ended September 30, 2007, as compared to net interest income of $0.1 million for the three months ended September 30, 2006. During the quarter ended September 30, 2007, the Company recognized $0.4 million of interest income associated with its investments and a $2.7 million reduction in non-cash interest expense for the net decrease in the fair value of warrants issued in connection with the February and June 2007 financings.

The foreign exchange loss was $0.8 million in the third quarter of 2007, compared to a foreign exchange gain of $0.2 million in the third quarter of 2006. The increase in 2007 was due to higher spreads between the value of the U.S. dollar and the Euro compared to the prior year as the dollar denominated inter-company loan between the Company's subsidiaries is revalued each quarter based on changes in the value of the dollar versus the Euro, with all related changes
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 SIMpalm, ... updated payment app for Forte Payment System. Forte Mobile ... ACH payments on iPhone, iPod and iPad. The ... been recently updated by SIMpalm. This update was for ... currently supported on iOS 4.3 and is available to ...
(Date:7/22/2014)... treatment and cardiovascular risk assessment state that men have ... cardiovascular disease or of having a heart attack or ... (based on age, smoking history, and cholesterol and blood ... and how aggressively to treat high cholesterol are examined ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 ... ( http://www.risperdallawsuitcenter.com/ ) in the Philadelphia ... to deny punitive damages in cases alleging the ... growth), Bernstein Liebhard LLP reports. In an Order ... denied a plaintiffs’ request to certify the matter ...
(Date:7/22/2014)... 22, 2014 The park is the ... Kendalltown Homeowners Association, Inc., made a recent ... community with the purchase of playground equipment from American ... in beautiful Miami Florida, and is a 475-unit community ... the surrounding landscape has created a tropical paradise with ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... cancer drugs had yesterday won the final draft of approval ... ,The National Institute for Health and Clinical Excellence ... the use of three types of aromatase inhibitors in postmenopausal ... drugs would act by reducing the risk of tumors spreading ...
... is for hiking and camping, but it brings with it ... In order to prevent such illnesses, researchers //are looking at ... tea and vitamins C and E in preventing infection by ... Infectious Disease, part of the National Institutes of Health, awarded ...
... The central government will send an advisory to all ... aerated soft drinks //after an independent report found heavy ... an advisory to all state governments to educate the ... aerated soft drinks," Health Minister Anbumani Ramadoss told reporters ...
... study to be published in the August 15 issue of ... The Heart Research Institute in Sydney have warned// that a ... of burger can be sufficient enough to cause heart attack. ... 18 and 40, the researchers were shocked to find that ...
... Chairman, Eddie Thompson, who was diagnosed with prostate cancer ... for the disease at Ninewells Hospital. ,In a ... behalf last night, details of his illness were released ... media about his health. ,The new ...
... out some alarming statistics regarding the HIV and AIDS status ... ,Dr. Sheela Basrur, Ontario's chief medical officer, said, ... living with HIV and AIDS has increased in part because ... the mortality rates have been reduced through the introduction of ...
Cached Medicine News:Health News:Antioxidants Could Halt Rocky Mountain Spotted Fever 2
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... 2014 BiologicTx ® today announced their ... Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching ... 9 at the Miami Transplant Institute, located at Jackson ... Kidney Paired Donation (KPD) is an ... kidney transplant with one another due to incompatible blood ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3
... July 12, 2011 Sevocity, the leader in ... v11.1 has achieved full certification through the Certification ... a CCHIT Certified® 2011 Ambulatory EHR.  Sevocity v11.1 ... the highest level awarded by CCHIT.  The Certification ...
... 12, 2011 ,   ... are,pleased to announce that they have been engaged ... apricitabine (ATC), a late-stage,novel treatment for HIV infection. ... the,healthcare and investment business sectors. Dr ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: